1. Extracellular Ubiquitin(1–76) and Ubiquitin(1–74) Regulate Cardiac Fibroblast Proliferation
- Author
-
Vladimir B. Ritov, Edwin K. Jackson, Delbert G. Gillespie, and Eric Mi
- Subjects
0301 basic medicine ,Agonist ,Receptors, CXCR4 ,Cardiac fibrosis ,medicine.drug_class ,Dipeptidyl Peptidase 4 ,Blood Pressure ,030204 cardiovascular system & hematology ,Insulysin ,Rats, Inbred WKY ,CXCR4 ,Article ,03 medical and health sciences ,0302 clinical medicine ,Ubiquitin ,Rats, Inbred SHR ,Internal Medicine ,medicine ,Extracellular ,Animals ,Neuropeptide Y ,Receptor ,Cells, Cultured ,Dipeptidyl peptidase-4 ,Cell Proliferation ,Dipeptidyl-Peptidase IV Inhibitors ,CXCR4 antagonist ,biology ,Chemistry ,Myocardium ,Sitagliptin Phosphate ,Fibroblasts ,medicine.disease ,Fibrosis ,Chemokine CXCL12 ,Rats ,Cell biology ,030104 developmental biology ,Hypertension ,biology.protein ,Signal Transduction - Abstract
SDF-1α (stromal cell–derived factor-1α) is a CXCR4-receptor agonist and DPP4 (dipeptidyl peptidase 4) substrate. SDF-1α, particularly when combined with sitagliptin to block the metabolism of SDF-1α by DPP4, stimulates proliferation of cardiac fibroblasts via the CXCR4 receptor; this effect is greater in cells from spontaneously hypertensive rats versus Wistar-Kyoto normotensive rats. Emerging evidence indicates that ubiquitin(1–76) exists in plasma and is a potent CXCR4-receptor agonist. Therefore, we hypothesized that ubiquitin(1–76), similar to SDF-1α, should increase proliferation of cardiac fibroblasts. Contrary to our working hypothesis, ubiquitin(1–76) did not stimulate cardiac fibroblast proliferation, yet unexpectedly antagonized the proproliferative effects of SDF-1α combined with sitagliptin. In this regard, ubiquitin(1–76) was more potent in spontaneously hypertensive versus Wistar-Kyoto cells. In the presence of 6bk (selective inhibitor of insulin-degrading enzyme [IDE]; an enzyme known to convert ubiquitin(1–76) to ubiquitin(1–74)), ubiquitin(1–76) no longer antagonized the proproliferative effects of SDF-1α/sitagliptin. Ubiquitin(1–74) also antagonized the proproliferative effects of SDF-1α/sitagliptin, and this effect of ubiquitin(1–74) was not blocked by 6bk and was >10-fold more potent compared with ubiquitin(1–76). Neither ubiquitin(1–76) nor ubiquitin(1–74) inhibited the proproliferative effects of the non-CXCR4 receptor agonist neuropeptide Y (activates Y 1 receptors). Cardiac fibroblasts expressed IDE mRNA, protein, and activity and converted ubiquitin(1–76) to ubiquitin(1–74). Spontaneously hypertensive fibroblasts expressed greater IDE activity. Extracellular ubiquitin(1–76) blocks the proproliferative effects of SDF-1α/sitagliptin via its conversion by IDE to ubiquitin(1–74), a potent CXCR4 antagonist. Thus, IDE inhibitors, particularly when combined with DPP4 inhibitors or hypertension, could increase the risk of cardiac fibrosis.
- Published
- 2018
- Full Text
- View/download PDF